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NEOPLASIA
Skin homing of Se´zary cells involves SDF-1–CXCR4 signaling
and down-regulation of CD26/dipeptidylpeptidase IV
Maria Grazia Narducci, Enrico Scala, Antonella Bresin, Elisabetta Caprini, Maria Cristina Picchio, Daniele Remotti, Gianluca Ragone,
Francesca Nasorri, Marina Frontani, Diego Arcelli, Stefano Volinia, Giuseppe Alfonso Lombardo, Giannandrea Baliva, Monica Napolitano,
and Giandomenico Russo
Se´zary syndrome (SS) is a rare form of
cutaneous T-cell lymphoma (CTCL) char-
acterized by a distinct metastatic pattern
mainly involving blood and skin. Chemo-
kines and their receptors play a critical
role in cellular recruitment and homing to
tissues and in the metastatic process of
several tumors including non-Hodgkin T-
cell lymphomas (NHLs). Here we report
that SS cells express a functionally active
CXCR4 and that its ligand SDF-1 is abun-
dantly produced in the skin, which repre-
sents the main destination of SS cell
spreading. SDF-1 is normally inactivated
by proteolytic cleavage by the CD26/
dipeptidylpeptidase IV (DPPIV). The lack
of CD26 from the cell surface is a hall-
mark of circulating SS cells. We also
show that the CD26 phenotype is main-
tained also in skin-infiltrating neoplastic
T lymphocytes and that SS-affected indi-
viduals exhibit a reduced activity of
plasma soluble CD26. Finally, we observe
that the addition of soluble CD26 reduces
the migratory response of SS cells to
SDF-1 whereas the inhibition of the CD26
peptidase activity in Hut78, a CD26CTCL
cell line, enhances the SDF-1–induced
migration of these cells. Our findings
suggest that the SDF-1–CXCR4 axis could
play an important role in skin homing of
SS through the regulatory activity of CD26.
(Blood. 2006;107:1108-1115)
© 2006 by The American Society of Hematology
Introduction
Cutaneous T-cell lymphomas (CTCLs) are a heterogeneous group
of non-Hodgkin lymphomas (NHLs) that show a considerable
variability in clinical presentation, histology, immunophenotype,
and prognosis. They represent a clonal malignancy1 of CD4
helper T cells2,3 with a memory phenotype4 and tendency to
accumulate in the skin.5
Mycosis fungoides (MF) and Se´zary syndrome (SS) are the 2
major clinical variants of CTCLs. While MF shows a skin-
restricted infiltration of the clonal T-cell population and an indolent
course, SS is a leukemic and erythrodermic variant of CTCL
characterized by the presence of tumor lymphocytes in the skin,
lymph nodes, and peripheral blood. These tumor cells, named SS
cells, have major abnormalities like a low mitotic index, aberrant
but nonuniform chromosomal alterations,6 monoclonal rearrange-
ment7 with a loss of T-cell receptor repertoire complexity8 and loss
of surface molecules such as CD7, CD26, and CD49d.9-11 SS cells
mainly localize to the skin and express cutaneous lymphocyte-
associated antigen (CLA) that has been implicated in skin-specific
homing patterns.4,9 However, the mechanisms underlying the
accumulation of these atypical lymphocytes to the skin are poorly
defined. Extravasation and active locomotion of malignant lympho-
cytes could suggest the involvement of secreted factors such as
chemokines. Chemokines regulate multiple cell functions, includ-
ing cell chemotaxis, proliferation, and apoptosis, and are involved
in leukocyte transendothelial migration and homing to tissues.
These biologic activities are mediated through their interaction
with G protein–coupled chemokine receptors expressed by
target cells such as leukocytes, hematopoietic cells, neuronal
cells, glial cells, and cells of the vasculature.12 Recent studies
have also shown that chemokines and their receptors are
implicated in tumor cell growth, angiogenesis, and metastasis.13
Investigation of expression of chemokine receptors has been
performed in extracutaneous NHLs. Expression of CCR4 and its
ligand TARC/CCL17 was found in CTCLs such as SS and MF14
while CCR3 and its ligand eotaxin/CCL11 were detected in
cutaneous CD30 T-cell lymphoma.15
One of the hallmarks of SS cells is the loss of CD26/
dipeptidylpeptidase IV (DPPIV) from the cell surface,9,11 a mem-
brane-bound protease that, as recently demonstrated, is able in vitro
to cleave and inactivate SDF-1, the ligand of the chemokine
receptor CXCR4.16,17
Thus, we have hypothesized that a chemokine-mediated mecha-
nism and, particularly, the CXCR4–SDF-1 axis could play a role in
SS cells’ skin homing. Here we report that CXCR4 is expressed and
functionally active in SS cells and that the CXCR4 ligand SDF-1 is
abundantly expressed in the skin of affected patients. Moreover, we
confirm18 that neoplastic skin-infiltrating lymphoid cells are CD26,
similar to circulating SS cells, and that SS patients have a reduced
activity of the soluble CD26/DPPIV enzyme. The importance of
the CD26 role is further demonstrated by either the reduced
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SDF-1–induced chemotaxis of SS cells following the addition of
soluble CD26 or the increased migratory response of Hut78, a
CD26 CTCL cell line, after the CD26 activity inhibition.
Materials and methods
Blood samples
We analyzed blood samples from 12 patients affected by SS recruited from
Istituto Dermopatico dell’Immacolata (IDI) after obtaining their informed
consent. Diagnosis of SS was based on clinical criteria (erythroderma,
pruritus, palmoplantar keratoderma, diffuse adenopathies), histologic data
(cutaneous epidermotropic T-cell lymphoma), and biologic criteria repre-
sented by CD4/CD8 ratio greater than 10, percentage of T cells with a
CD4/CD8CD7 phenotype greater than 40%, and detection of circulat-
ing T-cell clones identified by FACS-V repertoire analysis. Only one
patient had been treated by chemotherapy at the time of analysis. All
patients included in this study were enrolled in clinical protocols approved
by the Instituto Dermopatico dell’Immacolata (IDI-IRCCS) Investigational
Review Board. The characteristics of the patients are listed in Table 1.
Cell line
Hut78 from American Type Culture Collection (ATCC no. TIB161; Manassas,
VA), a human cell line established from peripheral blood of CTCL patients, was
grown in complete RPMI 1640 (Sigma-Aldrich, St. Louis, MO) supplemented
with 10% of fetal bovine serum (Gibco, Grand Island, NY).
Flow cytometry of Se´zary cells
Peripheral blood mononuclear cells (PBMCs) from blood of 12 SS patients
and 10 healthy donors used as controls were studied in detail for T-cell
clonality by the detection of a dominant TCR-V rearrangement using a
panel of 23 V monoclonal antibodies (MoAbs) (Immunotech, Marseilles,
France) as previously described.9 Polymerase chain reaction (PCR) analy-
sis, direct sequencing, and spectratyping also confirmed clonality of SS
cells.9 To study chemokine receptors’ expression within the neoplastic
T-cell clone(s), we then performed a 3-color flow cytometry analysis using
TCR-V MoAbs in combination with fluorescein isothiocyanate (FITC)–
conjugated anti-CD3; R-phycoerythrin (PE)–conjugated anti-CXCR3, anti-
CXCR4, anti-CCR1, anti-CCR2, anti-CCR3, anti-CCR4, anti-CCR5,
anti-CCR6, anti-CCR7, and anti-CCR8; and peridin chlorophyll protein
(PCP)–conjugated anti-CD4 and anti-CD8 (Becton Dickinson, Heidel-
berg, Germany).
Quantitative analysis for 3-color flow cytometry was carried out using a
FACScan instrument (Becton Dickinson). At least 10 000 events were
acquired in list mode, and all data were analyzed by the CellQuest software
(Becton Dickinson). Live lymphomonocytes were electronically gated by
forward and right angle scatters. Results are listed in Table 2.
Chemotaxis assay
PBMCs isolated from 7 SS patients and 4 healthy donors were allowed to
migrate to different concentrations of SDF-1 (R&D Systems, Minneapolis,
MN) in a chemotaxis assay as previously described.19 Briefly, chemotaxis
was performed using 24-well transwell inserts with 5 m pore size filters
(Corning Costar, Corning, NY). SDF-1 at 0, 5, 100, 300, and 500 ng/mL
was added to the lower chamber in 0.6 mL migration medium (MM)
composed of Iscove medium, 0.5% FBS, and 25 mM HEPES. Cells from
SS patients and healthy controls were washed twice and resuspended at
107/mL in MM; 100 L of cell suspension was placed in the upper
chamber and allowed to migrate for 2 hours at 37°C. CD4 cells that
migrated into the lower chamber were counted with FACScan for 60
seconds at a flow rate of 60 mL/min, as described.20 Results are shown
as migration index, which represents the ratio between the number of
cells that migrated in the presence of SDF-1 and the number of cells that
migrated in response to MM alone.
PBMCs from 3 SS patients and controls were evaluated for their ability
to migrate in response to SDF-1 in the presence or absence of soluble CD26
(sCD26) (Alexis Biochemicals, San Diego, CA). SDF-1 alone or SDF-1
mixed with sCD26 at a molecular ratio of 200:1 and 20:1, respectively, was
resuspended in 100 mM Tris-HCl (pH 8) in a final volume reaction of 15
L. After 1 hour of incubation at 37°C, the mixtures were diluted in MM
and added to the lower chamber in a final volume of 600 L. Chemotaxis
assay was performed at 37 °C for 2 hours.
Three independent experiments were performed in duplicate, and
migrated cells were counted as described above. The results are shown as
migration index, and statistical analysis was made using the Student t test.
Hut78 chemotaxis was performed using a 24-well transwell insert with
8-m pore size filters. Inhibition of endogenous CD26 activity on Hut78
cells was accomplished by pretreating cells with 5 mM of specific inhibitor
Diprotin A (Sigma-Aldrich) for 15 minutes at 37°C in 5% of CO2. Diprotin
A was kept throughout the assay. Chemotaxis was performed in the
presence or absence of Diprotin A and SDF-1 at 50 ng/mL. Three
independent experiments were performed, and migrated cells were counted
by a hemocytometer. The results are shown as migration index, and
statistical analysis was made using the Student t test.
Immunohistochemistry and immunofluorescence
Biopsies of SS patients were selected from the files of the Service of
Pathology of the IDI. Pathological specimens were classified according to
the European Organization for Research and Treatment of Cancer (EORTC)
classification.5
According to standard protocols for immunohistochemical studies, the
paraffin sections were heated for 1 hour at 55°C. After dewaxing, the slides
were rehydrated through a graded ethanol series and distilled water,
immersed in PBS (pH 7.4), and then boiled for 10 minutes in EDTA buffer
(pH 8.0). Endogenous peroxidase was blocked with 0.3% hydrogen
peroxide, and nonspecific binding was blocked with 10% normal serum.
Immunostaining for SDF-1 was performed on 5 SS and 10 MF samples by
incubating with anti–human SDF-1 antibody (R&D Systems) or with an
isotype-matched negative control. Using streptoavidin-biotin peroxidase
labeling method (DAKO, Fort Collins, CO) we performed SDF-1 immuno-
histochemical stainings. Sections were counterstained with hematoxylin.
For CXCR4 immunofluorescence studies, frozen tissue sections (5 M)
from 5 SS skin biopsies were fixed in acetone at 20°C for 10 minutes.
After the preincubation with PBS/BSA plus 10% of horse serum for 1 hour
at room temperature (RT) to inhibit unspecific binding, sections were
incubated overnight at 4°C with a mouse anti–human CXCR4 Ab (R&D
Systems) followed by incubation with a horse biotinylated anti–mouse and
avidin D–Texas Red–conjugated Ab (Vector Laboratories, Burlingame,
CA). T lymphocytes were immunostained by incubation with the mouse
anti–human CD3 (DAKO) for 30 minutes at RT followed by incubation
with biotinylated anti–mouse (DAKO) and avidin D–FITC–conjugated Ab
(Hoechst; Vector Laboratories, Burlingame, CA). Nuclei were counter-
stained with Hoechst, and sections were analyzed by fluorescence micros-
copy (Axioplan 2; Zeiss, Jena, Germany). For CD26 immunofluorescence
studies, frozen tissue sections (5 M) from 5 SS skin biopsies were
incubated overnight at 4°C with a mouse anti–human CD26-antibody
(Ab)–FITC conjugated (Exalpha Biologicals, Maynard, MA) followed by
incubation with a rabbit anti–FITC and a goat anti–rabbit FITC conjugate
(Jackson ImmunoResearch Laboratories, Bar Harbor, ME). T lymphocytes
were immunostained by incubation with the mouse anti–human CD3 for 30
minutes at RT followed by incubation with a goat anti–mouse Cy5 (Jackson
ImmunoResearch Laboratories). Nuclei were counterstained with pro-
pidium iodide (PI) (2 g/mL), and sections were analyzed by confocal
microscopy (Zeiss LSM 510 Meta).
In situ hybridization
In situ hybridization was performed on frozen sections from 5 SS skin
biopsies according to the method already described.21 FITC-labeled sense
and antisense riboprobes were synthesized by in vitro transcription of a
447-bp coding fragment of the human SDF-1 cDNA cloned into TA vector
(Invitrogen, Carlsbad, CA). Linearized plasmids were transcribed by SP6
and T7 polymerase (Roche, Milan, Italy). The hybridization signals were
detected using a rabbit anti-FITC Ab and FITC-conjugated goat anti–rabbit
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Ab. Neoplastic T lymphocytes, already evaluated by serial histologic
sections of the same specimens, were immunostained by incubating a
mouse anti–human CD3 and a Cy3–conjugated anti–mouse Ab (Jackson
ImmunoResearch Laboratories). Nuclei were stained by PI (2 g/mL).
Preparations were analyzed using a confocal microscope (Zeiss LSM
510 Meta).
CD26/DPPIV activity
CD26/DPPIV activity was assayed on plasma of 11 SS patients, 7 MF
patients, and 7 healthy donors using Gly-Pro-p-nitroanilide (Gly-Pro-pNA)
(Sigma-Aldrich) as chromogenic substrate. Eight microliters of plasma was
incubated at 37°C for 10 to 60 minutes with 4 mM Gly-Pro-pNA in 100 L
PBS buffer (pH 7.4) containing 10 mg/mL BSA into 96-well flat micro-
plates. Proteolytic activity was determined by monitoring pNA release with
spectrophotometry at 405 nm. Inhibition of Gly-Pro-pNA cleavage was
determined in the presence of 4 mM Diprotin A preincubated for 15 minutes
at 37°C prior to the addition of the substrate. Tests were run in triplicate.
Absorbance was measured at 405 nm by microplate reader (Bio-Rad,
Hercules, CA).
Statistical analysis
Results are expressed as mean plus or minus SD or SEM of 3 or more
experiments performed in triplicate. Statistical analysis was performed
using the 2-tailed Student t test.
Results
CXCR4, CCR4, and CCR7 receptors are expressed by a high
percentage of circulating Se´zary cells
We have analyzed 12 patients with SS, diagnosed by both clinical
and morphologic criteria (Table 1), and 10 healthy donors as
controls for chemokine receptor expression.
T-cell clonality was assessed by flow cytometric analysis of the
TCR-V repertoire using a panel of TCR-V antibodies that
covers 65% to 70% of all TCR-V domains on CD3CD4
peripheral lymphocytes from patients and healthy controls. Nine of
the 12 SS patients showed a restricted TCR-V reactivity ranging
from 54% to 98% with a V2 expansion observed in 3 cases (Table
1). Clonality was also confirmed through PCR, direct sequencing,
and spectratyping analysis (not shown). TCR-V repertoire analy-
sis failed to identify a clonal population in 3 examined patients
(case nos. 1, 2, and 11). Thus, in these 3 latter patients, we applied,
as previously described,9 an indirect approach probing all the
circulating CD3/CD4 cells with a mixture of all commercially
available V MoAbs in a single reaction. This let us detect an
extremely reduced proportion of stained cells (less than 5%
compared with about 70% in healthy donors). This result is
compatible with the presence of a large unreactive T-cell popula-
tion undetectable by the current panel of antibodies.22
To define the phenotype of these expanded tumor cells, we used
a 3-color fluorescence-activated cell sorter (FACS) analysis ap-
proach, employing, for each patient, the specific reactive VMoAb
in combination with CXCR3, CXCR4, and CCR1-CCR8 chemo-
kine receptors.
As shown in Table 2, we found that CCR4, CCR7, and CXCR4
were consistently expressed within the specific TCR-V–positive
population detected in SS patients. CCR4 expression ranged from
31% to 100% with an average value of 80% 25% (versus
27% 5.1% of healthy polyclonal controls), CCR7 from 24% to
97% with an average value of 74% 24% (versus 65% 12.7%
of controls), and CXCR4 from 36% to 95% with an average value
of 63%  21% (versus 64%  7.7% of controls). CCR1, CCR2,
CCR3, CCR6, and CCR8 were absent in all SS patients,
similarly to controls. Heterogeneity was otherwise observed in
the expression of CCR5 and CXCR3. CCR5, in fact, was absent
in all patients with the exception of patient no. 8 (with 96% of
positive cells), whereas CXCR3 was found in 3 of 12 samples
ranging from 18% to 52%.
Similar data, confirming the expression of all chemokine
receptors investigated, were supported at the RNA level by the use
Table 1. Patient characteristics
Patient
Sex/age,
y
V
family
V
clonal,
%
V normal,
range (%*)
Absolute
no.
CD3CD4
V
CD4/
CD8
ratio T/N/M
Disease
duration,
mo
Current
disease Current therapy
Previous
therapy
1 F/61 Failed — — — 96 T4/N0/M0 38 Progress 30 ECP
steroids syst
ECP, IFN,
steroids syst
2 M/49 Failed — — — 7 T4/N1/M0 8 Steady 5 ECP IFN
steroids syst
Chemotherapy
3 F/61 13.6 98 0.1-3.6 (1.5) 1 348 16 T4/N0/M0 46 Steady 30 ECP IFN
steroids syst
ECP, IFN,
steroids syst
4 M/73 2 83 0.7-20.5 (5.6) 3 763 29 T4/N0/M0 46 Steady 1 ECP
steroids syst
None
5 M/56 2 92 0.7-20.5 (5.6) 3 162 96 T4/N0/M0 10 Steady 1 ECP
steroids syst
Chemotherapy
steroids syst
6 F/58 7.2 95 0.1-5.7 (0.9) 13 534 95 T4/N1/M0 12 Progress 1 ECP
steroids syst
IFN steroids
syst retinoid
7 M/45 5.1 68.5 1.2-6.1 (2.7) 2 748 17 T4/N0/M0 3 Progress 5 ECP IFN None
8 M/66 1 80 2.5-7.9 (3.8) 2 590 15 T4/N0/M0 13 Progress 1 ECP IFN steroids
syst PUVA
9 M/45 17 91 1.7-23.2 (4.7) 2 915 24 T4/N2/M0 0 Beginning 1 ECP  IFN Chemotherapy
PUVA
10 M/60 2 54 0.7-20.5 (5.6) 1 128 8 T4/N0/M0 0 Beginning IFN None
11 M/62 Failed — — — 48 T4/N1/M1 6 Steady 1 ECP IFN Chemotherapy
12 M/70 12 88 0.3-4.5 (1.3) 9 685 18 T4/N0/M0 0 Beginning 1 ECP  IFN None
According to the EORTC classification, all patients had SS.
ECP indicates extracorporeal photopheresis; IFN, interferon ; PUVA, psoralens ultraviolet A; syst, systemic; and progress, that disease is progressing.
*The percentage (rangemedian) of polyclonal TCR V T cells expressing the indicated TCR V gene observed in healthy controls.
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of Affymetrix U133A Gene Chips (Affymetrix, Santa Clara, CA)
on a group of 12 SS patients (data not shown).
CXCR4 receptor is expressed by skin-infiltrating neoplastic T
lymphocytes of SS patients
Because roles of CCR4 and CCR7 have been partially disclosed
by Ferenczi et al,14 Kallinich et al,23 and Sokolowska-Wojdylo,24
we focused our attention on possible function of CXCR4 and its
ligand SDF-1 in SS. Therefore, we first investigated whether
CXCR4 was also expressed by skin-infiltrating neoplastic T
lymphocytes by performing CXCR4 immunofluorescence on 5
frozen SS skin biopsies.
The morphologic features of cell malignancy were determined
by histologic analysis performed with hematoxylin-eosin staining
shown in Figure 1A-B. The immunofluorescence staining clearly
demonstrated the CXCR4 expression in dermal/epidermal-
infiltrating neoplastic T lymphocytes (Figure 1C), which were
recognized also by a CD3 staining (Figure 1D). CD26 was absent
on these atypical T lymphocytes while it was abundantly expressed
in CD3 cells. (Figure 1E). In situ hybridization of SDF-1 mRNA
also showed no expression in SS skin-infiltrating neoplastic T
lymphocytes (Figure 1F).
SDF-1 is a chemotactic factor for circulating SS cells
To assess whether CXCR4 expressed by SS cells was functionally
active, we analyzed circulating T lymphocytes in a chemotaxis
assay in response to SDF-1.
A total of 7 SS cases and 4 healthy controls were studied.
Results shown in Figure 2A revealed the ability of PBMCs from all
SS-affected individuals (7 of 7) to migrate toward SDF-1 with a
typical bell-shaped dose-response curve peaking at 300 ng/mL. As
expected, PBMCs from healthy donors also efficiently migrated to
SDF-1 although migration indexes were lower than in SS PBMCs.
(Figure 2A). Cytologic evaluation of SS cells that migrated into the
lower chambers confirmed their morphologic neoplastic features
(Figure 2B).
In addition to chemoattraction, SDF-1 might also contribute to the
metastasis process acting either as a survival factor or by affecting tumor
cell apoptosis.25,26 To evaluate such a possibility, we cultured PBMCs
from 6 SS patients and 6 healthy donors in serum-free conditions and in
media supplemented with 10% FBS in the presence of 100 and 300
ng/mLSDF-1.After 3 and 6 days of culture, the cells were stained with a
PE conjugate anti-CD4, annexin V–FITC, and PI and were evaluated for
apoptosis by FACS analysis. No significant differences in cells undergo-
ing apoptosis were observed between SDF-1–stimulated and unstimu-
lated CD4 neoplastic cells at all doses of SDF-1 tested (not shown).
SDF-1 is abundantly expressed in the skin of SS patients
but is not constitutively produced by neoplastic
T lymphocytes colonizing the skin
Because SS cells can migrate in vitro in response to SDF-1, we
determined whether this chemokine was expressed in the skin of SS
patients where it could possibly be involved in the recruitment of
neoplastic cells. To this aim, we used immunohistochemistry (IHC)
analysis to determine the expression levels of SDF-1 in lesional
skin biopsies of CTCLs as well as in normal and inflamed skin
control samples. The histopathological sections examined were
from 5 patients with SS and 10 patients with MF, because they
represent 2 commonly associated diseases sharing many morpho-
logic and biologic abnormalities.27 In substantial agreement with
previously described data,28 we found that SDF-1 is normally
expressed in epithelial, dendritic, endothelial, and small perivascu-
lar lymphocyte cells of both healthy and inflamed skin (Figure
3A-B); SDF-1 immunoreactivity, in all cases of SS and MF, was
strongly associated with the dermal/epidermal malignant lympho-
cyte infiltrate as shown in Figure 3C-F. Differently from normal
lymphocytes, which show a uniform SDF-1 localization both into
the cytoplasm and on the cell surface (Figure 3B), neoplastic cells
in some cases exhibited a dotlike immunostaining (Figure 3E),
possibly representing the consequence of a CXCR4 receptor
polarization to the leading edge in response to the chemotactic
SDF-1 stimulus.29,30
To establish whether SDF-1 immunoreactivity shown by skin
neoplastic T lymphocytes reflected the chemokine uptake from the
extracellular environment31 or was the consequence of autocrine
synthesis, we performed an in situ hybridization on 5 frozen
samples obtained from the same patients already evaluated by
SDF-1 IHC. Confocal microscopy analysis failed to reveal any
signal corresponding to a specific SDF-1 mRNA hybridization
associated with the neoplastic T lymphocytes (Figure 1F). In
keeping with this result, microarray analysis showed comparable
Table 2. Expression of chemokine receptors on circulating Se´zary cells
Within TCR-VCD3CD4, %
CXCR3 CXCR4 CCR1 CCR2 CCR3 CCR4 CCR5 CCR6 CCR7 CCR8
Patient no.
1 1.5* 95* 0* 1* 0* 97* 0.9* 0* 96* 0*
2 8* 82* 0* 0.2* 0* 31* 1* 0* 38* 0.8*
3 1 76 0 0 0 78 0.7 0 82 2
4 7 92 0 0 0 63 3.5 0 87 0
5 0 65 0 0 0 92 0.2 0 97 2
6 52 39 0 0.4 0 88 0.7 1.6 24 2
7 5 40 0 2 0 100 0 1 78 4
8 7 63 0 0 0 95 96 0 53 0
9 18 56 0 0 0 34 8 0.5 61 4
10 2 40 0 0 4 80 0 0 90 0
11 50* 71* 0* 0* 0* 100* 0* 0* 82* 1*
12 1 36 0 0 0 100 0 0 94 1.5
Healthy donors
Mean 35 64 0.7 1 0.1 27 11.2 5.4 65 0.76
SD 9 7.7 0.85 0.9 0.3 5.1 4 2.7 12.7 0.23
*Calculated within TCR-V unreactive T cells (see text).
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very low levels of SDF-1 mRNA in circulating SS cells and healthy
CD4 lymphocytes (data not shown)
CD26/DPPIV is not detectable in SS skin lesions, and its
soluble activity is reduced in SS/MF patients’ plasma
It has previously been described that the lack of CD26 is a
distinguishing feature of circulating SS cells,9,11 and several
studies have highlighted how CD26 is able to cleave SDF-1,
generating an inactive chemokine both in vitro and under
physiological conditions.16,17 We therefore investigated whether
SS-infiltrating neoplastic T lymphocytes also exhibited lack of
CD26 expression. Thus, frozen tissue sections were subjected to
CD26 immunofluorescence and analyzed by confocal micros-
copy. Results shown in Figure 1E revealed that CD26 is
undetectable in all SS patients’ skin biopsies.
Figure 1. CXCR4 and CD26 immunoreactivity and in situ hybridization analysis
of SDF-1 expression in an SS skin lesion. (A) Hematoxylin-eosin (H&E) staining of
serial sections from a frozen SS skin biopsy reveals the morphologic features of neoplastic
T lymphocytes that infiltrate the dermis (magnification  10/0.30 NA) and (B) (magnifica-
tion  40/0.75 NA) where eccrine glands are indicated by white arrows. (C-D) CXCR4-
CD3 immunofluorescence shows that the totality of neoplastic CD3-expressing T lympho-
cytes (green [D]) also express CXCR4 (red [C]) (magnification  40/0.75 NA). (E)
CD26-CD3 costaining analyzed by confocal microscopy shows that the totality of CD3
neoplastic T lymphocytes (red) do not express CD26 on their surface (green) while few
CD3-CD26 cells are present. (F) In situ hybridization analysis did not reveal any signal
corresponding to specific SDF-1 mRNA expression in neoplastic T lymphocytes.
SDF-1 mRNA is detected in epithelial cells of eccrine glands (arrows). Magnification
for panels E and F, 40/1.13 NA.
Figure 2. Chemotactic response to SDF-1 of circulat-
ing T lymphocytes isolated from SS patients and
healthy donors. (A) Chemotactic response of CD4 SS
cells and CD4 control cells following exposure to increas-
ing concentrations of SDF-1 (5 to 500 ng/mL) with a
typical bell-shaped response curve. Results (mean 
SEM from 3 separate experiments) are shown as migra-
tion indexes representing the ratio between the number of
cells that migrated in the presence of SDF-1 and the
number of cells that migrated in response to medium
alone. *Significant differences between controls (f) and
SS () by the Student t test (controls, n  4; SS, n  7;
P 	 .05). (B) Cells that migrated in the lower chambers in
response to SDF-1 were collected and stained with
hematoxylin-eosin to evaluate their morphologic fea-
tures. Original magnification 40.
Figure 3. Immunohistochemistry for SDF-1 in normal, inflamed, and neoplastic
CTCL skin biopsies. (A) Normal skin showing epithelial cells of eccrine glands with a
strong SDF-1 immunoreactivity associated with membrane and cytoplasm (magnifi-
cation 20/0.40 NA). (B) Chronic dermatitis showing endothelial cells of dermal
capillary vessels and scant perivascular lymphoid infiltrate with a strong SDF-1
immunoreactivity (magnification 20/0.40 NA). (C) SS skin lesion showing a strong
SDF-1 immunoreactivity associated with neoplastic T lymphocytes of pathognomonic
Pautrier microabscess and neoplastic T lymphocytes that infiltrate dermis and
epidermis (magnification 20/0.40 NA). (D) MF skin lesion showing an SDF-1
immunoreactivity associated with neoplastic T lymphocytes that infiltrate dermis and
epidermis (magnification  40/0.65 NA). (E) SS skin lesion showing neoplastic T
lymphocytes with an SDF-1 dotlike immunoreactivity (magnification  60/0.80 NA).
(F) SS skin lesion showing SDF-1 positivity associated with neoplastic T lymphocytes
infiltrating the dermis, whereas the intravascular neoplastic T lymphocytes appear
SDF-1 negative (magnification 20/0.40 NA).
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The precise source for plasma CD26 is unclear; it may derive
from all CD26-expressing cells that come into contact with blood.
Nevertheless, circulating neoplastic T lymphocytes in SS do not
express CD26, an immunologic feature that has been described also
in MF disease11,32; hence, we assessed whether soluble CD26/
DPPIV activity was detectable in the plasma of SS/MF patients.
Using the chromogenic substrate Gly-Pro-pNA, we monitored the
production of pNA determined by CD26/DPPIV cleavage and
found that SS/MF patients’ plasma displayed a lower CD26/DPPIV
activity than healthy controls (Figure 4). In particular, after 30
minutes of reaction, absorbance values (mean  SEM of 3
independent experiments) indicated a statistically significant enzy-
matic activity reduction of a mean of 26% (8.6% 0.43%) and
33% (7.4% 0.74%,) respectively, in MF and SS patients when
compared with controls (11.6% 1.3%). After 60 minutes we
observed a reduction of about 26% in both MF and SS. The
addition of CD26 antagonist, Diprotin A, to plasma reduced the
level of pNA over 95%, demonstrating the specificity of the assay
(not shown).
Lack of CD26 from the cell surface enhances the in vitro
migratory response of SS cells induced by SDF-1
Recently it has been demonstrated that N-terminal–truncated
SDF-1 fails to induce in vitro migration of CD34 hematopoietic
progenitor cells and that the inhibition (or loss) of CD26 activity on
these cells enhances their migratory response to SDF-1.33,34
To evaluate if exogenous CD26 activity could reduce the
migratory response of CD26-circulating SS cells induced by
SDF-1, we performed a chemotaxis assay using PBMCs from 3 SS
patients in response to SDF-1 in the absence and presence of
soluble CD26. As shown in Figure 5A, SDF-1 supplemented with
sCD26 at molecular ratios of 200:1 and 20:1 reduced the SDF-1
chemotactic activity, respectively, 44% and 65% if compared with
the response induced by SDF-1 alone. Similar results were
observed with PBMCs from healthy controls (not shown). Further-
more, to verify that the inhibition of CD26 activity could instead
improve the responsiveness to SDF-1 in SS cells, we performed a
chemotaxis assay using Hut78, a human CTCL cell line.
The immunophenotype characterization performed by a FACS
analysis revealed that, although Hut78 cells possess a typical
CD4, CD7, CXCR4 SS cell phenotype, they express CD26 on
their cell surface, and they were therefore used for CD26 inhibition
studies.
Although we assessed the chemotatic response of Hut78 to
different concentrations of SDF-1 (50 to 300 ng/mL), we observed
that Hut78 cells show the higher chemotactic activity in response to
50 ng/mL SDF-1. Treatment with 5 mM Diprotin A demonstrated
up to 3.1-fold of SDF-1–directed chemotactic activity (Figure 5B).
Discussion
Chemokine receptors have been involved in the regulation of tissue
homing, metastasis, proliferation, and apoptosis. In our attempt to
identify crucial molecules involved in the regulation of SS cell
functions, we analyzed the expression of several chemokine
receptors and found that CXCR4 was abundantly expressed by
circulating SS cells and skin-infiltrating neoplastic T lymphocytes.
CXCR4 activity is regulated by its interaction with the ligand
SDF-1, and this SDF-1–CXCR4 axis is essential for leukocytes
trafficking19 and can mediate both proliferative35 and apoptotic
stimuli25,26 in hematopoietic cells.
Furthermore, the CXCR4–SDF-1 axis is involved in the metas-
tasis of breast,36 lung,37 ovarian,38 pancreatic,39 neuroblastoma,40
renal,41 thyroid,42 rhabdomyosarcoma,43 prostate,44 and colorectal45
cancers as well as several types of lymphomas.46-49
In this study we have demonstrated that the expression of
CXCR4 might have a functional relevance in both circulating and
skin-infiltrating SS cells. Its ligand, SDF-1, that is expressed in skin
lesions of these patients but not in the circulating SS cells is a
potent inducer of chemotaxis of SS cells. Moreover, the absence of
CD26 peptidase, the lack of which is known to be a hallmark of
circulating SS cells, is potentially involved in SDF-1 processing.
Figure 4. Plasma CD26/DPPIV activity in SS and MF patients and healthy
donors. CD26 activity measured in the plasma of SS and MF patients and compared
with that of healthy donors. Using the chromogenic substrate Gly-Pro-pNA, the
production of pNA by CD26 activity was monitored at 405 nm. After 30 minutes of
reaction, adsorbance values (mean  SEM from 3 separate experiments) indicated
that MF and SS patients displayed, respectively, a significant reduction of CD26
activity of 26% (8.6%  0.43%) and 33% (7.4%  0.74%) when compared with
controls (116%  1.3%). After 60 minutes the reduction was about 26% in both MF
and SS. *Significant differences between MF/SS and controls by Student t test (MF,
n  7; SS, n  11; P 	 .05).
Figure 5. The effects of CD26 activity on chemotaxis of SS cells induced by SDF-1. (A) Chemotactic response of CD4 SS cells following exposure of SDF-1 (300 ng/mL)
in the absence or presence of soluble CD26 (sCD26), respectively, at a molecular ratio of SDF-1 and sCD26 of 200:1 and 20:1. Results (mean  SEM from 3 separate
experiments) are shown as migration indexes representing the ratio between the number of cells that migrated in the presence of SDF-1 alone or supplemented with sCD26
and the number of cells that migrated in response to medium alone. *Significant differences between SDF-1 supplemented with both sCD26 concentrations and SDF-1 alone
calculated by the Student t test (SS, n  3; P 	 .05). (B) Chemotaxis assay performed comparing Diprotin A–treated (f) and untreated () Hut78 cell line. Treatment with 5
mM Diprotin A enhances up to 3.1-fold of SDF-1–directed chemotactic activity. *Significant differences between untreated and treated Hut78 cells by the Student t test (n  6;
P 	 .05).
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Together, these findings suggest that CXCR4-mediated signals may
represent a homing mechanism of SS cells to the skin, their
preferred metastatic site.
One might argue that SDF-1 is constitutively expressed in a
number of tissues, including bone marrow and lung, yet Se´zary
cells rarely enter these tissues. This conundrum might be explained,
for example, by the coexistence of specific skin-homing receptors
such as CLA and CCR4, and of CXCR4, in SS cells. On the
contrary, the lack of SS spreading into other tissues may be dictated
by the absence of additional signals. In this regard, recently Xu et
al50 demonstrated that lymphocyte homing to bronchus-associated
lymphoid tissue (BALT) is dependent on CD49d-VCAM1 interac-
tion. Interestingly, CD49d is not present on the SS cell surface.9
In this study we also investigated several functional aspects of
CXCR4–SDF-1 interaction. One aspect, in our opinion, is given by
the mechanisms that inactivate SDF-1. In vitro, SDF-1 can be
enzymatically cleaved by a variety of proteases51 and, among these,
matrix metalloproteinases and CD26/DPPIV are well character-
ized.17,52 CD26 is absent on both circulating and skin-infiltrating SS
tumor cells. A soluble form of CD26 lacking the transmembrane
domain is also found in plasma and other biologic fluids. The origin
of this soluble form is not clear, although it could be generated by
the cleavage of CD26 expressed by cells in contact with the
blood.53 Therefore, the reduced level of CD26 activity that we
found in the plasma of both SS and MF patients could be secondary
to the diminished number of circulating CD26 cells present in
these variants of CTCLs.
The proteolytic cleavage of endogenous SDF-1 in the bone
marrow has been identified as a key modulator of hematopoietic
progenitor cell mobilization to peripheral blood.54-56 Further, the
increase in SDF-1 expression in ischemia has a critical role in
mobilization of endothelial progenitor cells (EPCs), recruitment to
the injury site, and differentiation into vascular cells.57-59 Recently,
functional studies have shown that the inhibition of CD26 enhances
the migratory response to SDF-1 in hematopoietic progenitor
cells.34 Interestingly, we have shown that the addition of soluble
CD26 reduces the SDF-1–induced chemotaxis of SS cells whereas
the inhibition of CD26 activity on Hut78, a CD26 CTCL cell line,
by a specific antagonist increases the migration response of these
cells to SDF-1 when compared with healthy CD4 cells. Thus,
these results support the hypothesis that CXCR4-mediated signals
may regulate CTCL skin accumulation and that the CD26 molecule
may play a role in this process. Furthermore, these data suggest that
the lack of CD26 from SS tumor cell surface might act as a
reinforcing mechanism of SDF-1–directed chemoattraction in
these patients and could also explain the abundance of this
chemokine detected at the skin level in SS patients. These results
also might assume relevance for MF, which, differently from SS,
has an indolent clinical course with slow progression, over years or
sometimes decades, from patches to more infiltrated skin plaques
and eventually tumor.5 Because high SDF-1 levels have been
detected in MF skin and a reduced soluble CD26 activity was
measured in MF patients’ plasma, the CXCR4-dependent skin-
homing mechanism hypothesized above for the SS could also apply
to this indolent variant of CTCL.
Cells that express both a growth factor and its receptor have the
potential for self-stimulatory or autocrine growth in normal or
malignant hematopoietic cells.60,61 In CTCL, for example, IL-15
has been shown to exert autocrine growth.62 Circulating SS cells
are usually in resting phase and unable to properly respond to T-cell
mitogen stimulations.63,64 On the contrary, neoplastic lymphocyte
proliferation is observable in skin infiltrates.65 We therefore
investigated whether SDF-1 may be produced by skin-infiltrating
tumor cells and found that, while neoplastic T lymphocytes filling
the capillary vessels do not express SDF-1, those infiltrating the
skin nearby are moderately positive for SDF-1, possibly suggesting
a chemokine uptake from the surrounding microenvironment as
described for other citokines/chemokines.31 It is in fact unlikely
that SS cells could acquire the ability to express SDF-1 once they
have infiltrated the skin, because no SDF-1 mRNA expression was
found in infiltrating neoplastic cells by in situ hybridization. Our
data suggest that no SDF-1–mediated autocrine regulation of SS
cell functions is likely to occur in the skin.
Unlike their normal CD4 counterparts, SS cells have pro-
longed life spans and are resistant to chemotherapeutic agent–
induced cell death.66 We have therefore investigated whether
SDF-1 could be involved in the regulation of apoptosis of SS cells
and found no significant differences between SS and healthy CD4
cells following in vitro SDF-1 stimulation.
In conclusion, these findings suggest that the SDF-1–CXCR4
axis, through the regulatory activity of CD26, may contribute to
CTCL cell skin recruitment and accumulation. Because SS cells
preferentially home and proliferate into skin, CXCR4 signaling
may contribute to CTCL disease progression. It can therefore be
hypothesized that blocking the CXCR4–SDF-1 axis, by means of
specific CXCR4 antagonists, could represent a useful tool to
interfere with tumor progression in CTCL patients.
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